
Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Central retinal vein occlusion (CRVO), a common retinal vascular disorder, has two types, namely, ischemic and non-ischemic, with some patients presenting intermediate features. Over 90% of patients with ischemic CRVO experience final visual acuity of 20/200 or worse. Anterior segment neovascularisation occurs in more than 60% of cases, with related complications typically arising within weeks to two years after the onset of the condition.
Base Year
Historical Year
Forecast Year
Expert Market Research's “Central Retinal Venous Occlusion Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of central retinal venous occlusion. It projects the future incidence and prevalence rates of central retinal venous occlusion across various populations. The study covers age, gender, and type as major determinants of the central retinal venous occlusion-affected population. The report highlights patterns in the prevalence of central retinal venous occlusion over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of central retinal venous occlusion in the 8 major markets.
Regions Covered
Central retinal venous occlusion (CRVO) occurs when the main vein draining blood from the retina becomes blocked, usually due to a blood clot. This blockage leads to impaired blood flow, causing retinal swelling, hemorrhages, and vision problems. Risk factors include high blood pressure, diabetes, glaucoma, and clotting disorders. Symptoms often include sudden, painless vision loss or blurring in one eye. CRVO is classified as non-ischemic or ischemic, with the latter posing a higher risk of severe vision loss. Treatment includes managing underlying conditions, anti-VEGF injections, or laser therapy to reduce complications.
Central retinal vein occlusion (CRVO) treatment aims to manage complications, improve vision, and prevent progression. Management includes anti-vascular endothelial growth factor (VEGF) injections, corticosteroids, and addressing risk factors like hypertension and diabetes to reduce recurrence or bilateral involvement. Corticosteroid implants may also be employed in specific cases. Addressing underlying risk factors, such as hypertension, diabetes, and glaucoma, is critical to reducing recurrence and preventing bilateral involvement. For non-ischemic CRVO, complete recovery occurs in only 10% of cases, while 50% experience 20/200 or worse vision, and 34% convert to ischemic CRVO within three years.
The central retinal venous occlusion epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for central retinal venous occlusion by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for central retinal venous occlusion and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
The central retinal venous occlusion epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
The epidemiology of central retinal vein occlusion (CRVO) varies globally, being the second most common retinal vascular disorder. Non-ischemic CRVO is more prevalent than the ischemic type. In the United States, Europe, Asia, and Australia, pooled data indicate CRVO affects 0.8 per 1,000 individuals. The Beaver Dam Eye Study reported a 15-year cumulative incidence of 0.5%. In Israel, the 4-year incidence is 2.14 per 1,000 individuals over 40 years, increasing to 5.36 per 1,000 above 64 years. In Australia, prevalence ranges from 0.7% at ages 49-60 to 4.6% in those over 80 years.
Country Specific Stats:
Country |
Prevalence (Unit) |
United States |
0.8 in 1000 |
United Kingdom |
XX |
Germany |
XX |
Italy |
XX |
France |
XX |
Spain |
XX |
Japan |
XX |
India |
XX |
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
Report Features |
Details |
Base Year |
2024 |
Historical Period |
2018-2024 |
Forecast Period |
2025-2034 |
Epidemiology Statistics Provided |
|
Segmentation Provided |
|
Geographies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 2,999
USD 2,699
tax inclusive*
Five User License
Five User
USD 4,399
USD 3,739
tax inclusive*
Corporate License
Unlimited Users
USD 5,799
USD 4,929
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share